Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dna Extraction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Dna Extraction. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-000592-24 Sponsor Protocol Number: MR308-3501 Start Date*: 2017-03-15
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Third Molar Tooth Extraction (...
    Medical condition: Acute pain after third molar tooth extraction; dental procedure must have involved extraction of at least two impacted third molars requireing bone removal. If only two impacted third molars are ex...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000023314 10066714 Acute pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000494-20 Sponsor Protocol Number: ABC-SE Start Date*: 2016-07-03
    Sponsor Name:Skåne University Hospital, Department of Oncology
    Full Title: A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Based Treatment with Focus on Mechanisms of Resistance to Endocrine Based Treatment (fulvestrant/aroma...
    Medical condition: Estrogen receptor positive metastatic or locally advanced inoperable breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001501-41 Sponsor Protocol Number: 156-13-208 Start Date*: 2016-01-16
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD), Patients with Increased Risk of Liver Injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002560-34 Sponsor Protocol Number: F1J-US-HMFR(b) Start Date*: 2008-09-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis
    Medical condition: Central neuropathic pain due to Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004486-40 Sponsor Protocol Number: R3918-PNH-2021 Start Date*: 2022-04-04
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) GR (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002761-33 Sponsor Protocol Number: R3918-PNH-2022 Start Date*: 2022-05-02
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGL...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) PL (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002388-13 Sponsor Protocol Number: AZA-JMML-001 Start Date*: 2015-02-20
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety and activity of azacitidine and to compare azacitidine to historical controls in pediatric subjec...
    Medical condition: newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054439 Juvenile chronic myelomonocytic leukemia LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023249 Juvenile chronic myelomonocytic leukaemia PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IE (Completed) AT (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) DK (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000308-17 Sponsor Protocol Number: GS-US-380-4030 Start Date*: 2017-07-05
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir D...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004094-52 Sponsor Protocol Number: R5713-5714-5715-ALG-2001 Start Date*: 2021-02-19
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
    Medical condition: Birch Pollen Allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BE (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003254-24 Sponsor Protocol Number: R668-AD-1224 Start Date*: 2015-03-12
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Moderate to severe atopic dermatitis (AD).
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Completed) NL (Completed) LV (Prematurely Ended) BE (Completed) PL (Completed) ES (Completed) RO (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004011-20 Sponsor Protocol Number: GS-US-380-1878 Start Date*: 2016-02-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000405-22 Sponsor Protocol Number: TE23 Start Date*: 2005-02-25
    Sponsor Name:Medical Research Council
    Full Title: TE23: Randomised Phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP chemotherapy in poor prognosis male germ cell tumours.
    Medical condition: Poor prognosis male germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043333 Testicular germ cell tumour mixed stage III LLT
    9.1 10015802 Extragonadal primary germ cell tumour mixed stage III LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001194-14 Sponsor Protocol Number: D8480C00051 Start Date*: 2006-10-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of AZD2171 when added to 5 fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) w...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006227-12 Sponsor Protocol Number: SPON408-07 Start Date*: 2008-03-18
    Sponsor Name:Cardiff University
    Full Title: A randomised, placebo controlled study of nebulised magnesium in acute severe asthma in children
    Medical condition: Acute severe asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002142-31 Sponsor Protocol Number: 547-SSE-301 Start Date*: 2016-11-16
    Sponsor Name:Sage Therapeutics
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS
    Medical condition: SUPER-REFRACTORY STATUS EPILEPTICUS (SRSE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10041962 Status epilepticus PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Completed) DK (Completed) ES (Completed) NL (Completed) FI (Completed) HU (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000138-33 Sponsor Protocol Number: R4461-PLD-20100 Start Date*: 2021-12-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
    Medical condition: Familial Partial Lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) DK (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing) AT (Completed) DE (Prematurely Ended) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003684-35 Sponsor Protocol Number: R2810-ONC-1763 Start Date*: 2018-07-10
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients wit...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) PL (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-022922-34 Sponsor Protocol Number: 3098006 Start Date*: 2011-03-01
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 ...
    Medical condition: Alzheimer’s disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001900-39 Sponsor Protocol Number: 11/0475 Start Date*: 2012-11-01
    Sponsor Name:University College London
    Full Title: A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of pat...
    Medical condition: Diffuse large B cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA